摘要
目的观察联合应用孟鲁司特钠和布地奈德治疗小儿咳嗽变异性哮喘的临床效果。方法以120例咳嗽变异性哮喘患儿为研究对象,根据PEMS 3.0软件包中随机数字表分为联合组与参考组,参考组实施常规治疗方案+布地奈德雾化治疗,联合组实施参考组治疗方案+孟鲁司特钠口服治疗。以临床效果、治疗前后肺功能指标变化及安全性作为指标评价两组的有效性及安全性。结果联合组疗效分布与参考组经秩和检验显示差异有统计学意义(P<0.05),前者总有效率远高于后者(P<0.05);治疗后联合组与参考组用力肺活量(FVC)和第1s用力呼气量(FEV1)均较治疗前远远升高(P<0.05),且治疗后联合组FVC、FEV1均远高于参考组(P<0.05);联合组不良反应发生率与参考组相近,无统计学差异(P>0.05)。结论对小儿咳嗽变异性哮喘联合应用孟鲁司特钠与布地奈德有效性和安全性均理想,且能够显著改善肺功能指标。
Objective To observe clinical effect of montelukast sodium combined with budesonide in treatment of cough variant asthma children. Methods Treat 120 cases cough variant asthma children as research objects, according to random digital table of PEMS3.0 software package, divide them into combination and reference group. Reference group was treated with routine therapy±budesonide, and combination group with combination group sheme and oral medication of montelukast sodium. Evaluate effectiveness and safety of two groups with indexes of clinical effect, pulmonary function changes before and after treatment and safety. Results Curative effect distribution of combination group and ranksum test of reference group showed difference had statistical significance(P<0.05), total effective rate of former was much higher than the latter(P<0.05); forced vital capacity(FVC) and the 1 st seconcd forced expiratory volume(FEV1) of combination and reference group was much higher than before treatment(P<0.05), and FVC, FEV1 of combination group was much higher than reference group(P<0.05); adverse reactions rate of combination group was similar to reference group, with no significant difference(P> 0.05). Conclusion Montelukast sodium combined with and budesonide is effective and safe for cough variant asthma children, and can improve pulmonary function index significantly.
出处
《智慧健康》
2017年第21期52-54,共3页
Smart Healthcare
